On May 23, 2018, Health Canada published Overview of the Reporting Adverse Reactions to Marketed Health Products - Guidance Document for Industry. “This guidance document provides market authorization holders (MAHs) with assistance on how to comply with the Food and Drugs Act, the Food and Drug Regulations and the Natural Health Products Regulations with respect to reporting adverse reactions (ARs) to marketed health products”, including: pharmaceutical drugs, biologics, radiopharmaceutical drugs and natural health products. These ARs are to be reported to the Canada Vigilance Program of the Marketed Health Products Directorate (MHPD) of Health Canada.
Related Publications & Articles
-
Health Canada proposes to amend the Food and Drug Regulations and Medical Devices Regulations to address shortages
On December 28, 2024, Health Canada published proposed amendments to the Food and Drug Regulations and Medical Devices Regulations to address therapeutic product shortages (see our previous article re...Read More -
Canadian Patent Office resumes granting of patents and is temporarily publishing list of pre-grant patents
The Canadian Patent Office has advised that as of January 14, 2025, it had granted patents for which final fees were processed in the old system.Read More -
Health Canada publishes guidance on submitting risk management plans
The agile licensing amendments to the Food and Drug Regulations include provisions requiring risk management plans for certain human drugs (RMP provisions). Those amendments will come into force on Ap...Read More